...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Volume

Another promissory note. Well, as long as they are unsecured I suppose it's all good. 

I believe the previous one was for ~$2 Mil CAN.

 

Koo

 

Share
New Message
Please login to post a reply